{"id":"d1c27f46-7c72-5965-a456-ccfb6428c99e","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-b12-neuropathy-prevalence","predicate":"associated_with","statement":"Neuropathy prevalence was higher in the metformin group among those with low B12 levels, and anaemia prevalence was higher in the metformin group though it did not differ by B12 status.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"aecf4bec-6adb-5f56-a831-40c1a659eee6","mechanism_event_label":"The people with both the drug and a low vitamin had more nerve disease.","subject":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"object":{"id":"fd60b638-44a9-5644-9de9-d0afbd881c2e","slug":"diabetic-peripheral-neuropathy-severity","display_name":"Clinical and electrophysiological severity of diabetic peripheral neuropathy","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"aecf4bec-6adb-5f56-a831-40c1a659eee6","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-b12-neuropathy-prevalence-event","event_type":"observed_intervention","label":"The people with both the drug and a low vitamin had more nerve disease.","description":"Neuropathy prevalence was higher in the metformin group among those with low B12 levels, and anaemia prevalence was higher in the metformin group though it did not differ by B12 status.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"b6d9b937-895d-5e0a-8cc5-0454a0b7d373","slug":"vitamin-b12","display_name":"Vitamin B12 (cobalamins)","entity_type_key":"chemical_species"},"role":"depleted_nutrient","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"fd60b638-44a9-5644-9de9-d0afbd881c2e","slug":"diabetic-peripheral-neuropathy-severity","display_name":"Clinical and electrophysiological severity of diabetic peripheral neuropathy","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/26900641.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"09cb74c29fe2d647d668d912a9a01962384e38bcc309a29c429d2caaed3048f1\", \"start_char\": 0, \"end_char\": 1842, \"text_sha256\": \"09cb74c29fe2d647d668d912a9a01962384e38bcc309a29c429d2caaed3048f1\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Secondary analysis of the Diabetes Prevention Program Outcomes Study over 13 years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Metformin 850 mg twice daily versus placebo, then open-label metformin","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Long-duration data. Neuropathy and anaemia were measured as prevalence, and the design cannot separate duration from cumulative dose.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The people with both the drug and a low vitamin had more nerve disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p26900641] Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. (2016). https://pubmed.ncbi.nlm.nih.gov/26900641/ DOI: 10.1210/jc.2015-3754","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole body","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"1823abe3-1375-50ea-a1de-1ae0efb34585","evidence_kind":"source_excerpt","locator":"Lines 1100-1111","start_line":1100,"end_line":1111,"excerpt":"### metformin-b12-neuropathy-prevalence\nNeuropathy prevalence was higher in the metformin group among those with low B12 levels, and anaemia prevalence was higher in the metformin group though it did not differ by B12 status.\nCondition category: biomarker_context\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: The people with both the drug and a low vitamin had more nerve disease.\norganism: Human\ntissue_or_cell_type: Whole body\nexperimental_model: Secondary analysis of the Diabetes Prevention Program Outcomes Study over 13 years\nlimitations: Long-duration data. Neuropathy and anaemia were measured as prevalence, and the design cannot separate duration from cumulative dose.\nexposure: Metformin 850 mg twice daily versus placebo, then open-label metformin\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/26900641.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"09cb74c29fe2d647d668d912a9a01962384e38bcc309a29c429d2caaed3048f1\", \"start_char\": 0, \"end_char\": 1842, \"text_sha256\": \"09cb74c29fe2d647d668d912a9a01962384e38bcc309a29c429d2caaed3048f1\"}\n[metformin-p26900641] Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. (2016). https://pubmed.ncbi.nlm.nih.gov/26900641/ DOI: 10.1210/jc.2015-3754","model_system":"Secondary analysis of the Diabetes Prevention Program Outcomes Study over 13 years","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p26900641] Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. (2016). https://pubmed.ncbi.nlm.nih.gov/26900641/ DOI: 10.1210/jc.2015-3754","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}